UNIVEST FINANCIAL Corp Has $2.43 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Key Points

• UNIVEST FINANCIAL Corp reduced its stake in Lantheus Holdings by 22.3%, now holding 24,882 shares valued at approximately $2.43 million.
• Lantheus has a consensus rating of "Moderate Buy" among analysts with a target price averaging $131.20, despite missing earnings and revenue estimates in its latest quarterly report.
• Insider Mary Anne Heino sold 26,066 shares of Lantheus at around $76.83 each, reducing her ownership by 7.56% to a total of 318,650 shares.

UNIVEST FINANCIAL Corp cut its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 22.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 24,882 shares of the medical equipment provider's stock after selling 7,159 shares during the quarter. UNIVEST FINANCIAL Corp's holdings in Lantheus were worth $2,428,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. State of Michigan Retirement System lifted its stake in shares of Lantheus by 0.6% in the 1st quarter. State of Michigan Retirement System now owns 16,600 shares of the medical equipment provider's stock valued at $1,620,000 after purchasing an additional 100 shares during the period. Signaturefd LLC increased its position in Lantheus by 36.5% in the 1st quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 116 shares in the last quarter. Foundry Partners LLC increased its position in Lantheus by 4.5% in the 4th quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock valued at $278,000 after buying an additional 133 shares in the last quarter. Nisa Investment Advisors LLC increased its position in Lantheus by 2.1% in the 1st quarter. Nisa Investment Advisors LLC now owns 6,691 shares of the medical equipment provider's stock valued at $653,000 after buying an additional 139 shares in the last quarter. Finally, Moody National Bank Trust Division increased its position in Lantheus by 1.0% in the 1st quarter. Moody National Bank Trust Division now owns 14,910 shares of the medical equipment provider's stock valued at $1,455,000 after buying an additional 141 shares in the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. William Blair reaffirmed a "market perform" rating on shares of Lantheus in a research report on Wednesday, July 16th. Wall Street Zen raised Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. B. Riley decreased their target price on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research report on Monday, June 23rd. Finally, Truist Financial decreased their target price on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $131.20.

Lantheus Stock Performance

Shares of LNTH opened at $71.19 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 5.46 and a current ratio of 5.74. The stock has a 50 day moving average price of $77.71 and a two-hundred day moving average price of $88.13. The firm has a market capitalization of $4.93 billion, a P/E ratio of 20.22 and a beta of 0.12. Lantheus Holdings, Inc. has a 52 week low of $69.12 and a 52 week high of $118.21.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The company had revenue of $372.76 million for the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The business's revenue for the quarter was up .8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.69 earnings per share. Equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Mary Anne Heino sold 26,066 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the transaction, the director directly owned 318,650 shares of the company's stock, valued at $24,481,879.50. This represents a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.